Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Trial Details

NCT ID

NCT04923542

Phase

PHASE1 / PHASE2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• Stereotactic Radiosurgery (SRS)
• Abemaciclib
• Endocrine therapy

Locations (sample)

• Tampa, Florida, United States|27.94752,-82.45843
• Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

• HR+ breast cancer to fulfill the requirement of HR+ disease, a breast cancer must express (≥ 1%), by immunohistochemistry (IHC), at least 1 of the …
• To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression o…
• ≤ 15 brain metastases eligible for stereotactic radiation
• Able to swallow oral medications

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.